The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Kelly McQuarrie
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - JJ Innovative Medicine; Merck Sharp & Dohme
 
Behzad Bidadi
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Chih-Chin Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christopher M. Black
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Anran Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yungan Tao
Honoraria - Merck Serono; Seagen
Consulting or Advisory Role - MSD Oncology
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology
 
Lisa F. Licitra
Honoraria - Adlai Nortye; ALTIS Omnia Pharma Service S.r.l.; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; AstraZeneca; Boehringer Ingelheim; Eisai; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Merck Healtcare KGaA; Merck Serono; Mirati Therapeutics; MSD; MSD; Novartis Farma S.p.a.; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Barbara Burtness
Consulting or Advisory Role - Abbvie; ALX Oncology; Arvinas; Coherus Biosciences; CUE Biopharma; Eisai; Genentech/Roche; IO Biotech; Janssen Oncology; Kura Oncology; Macrogenics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Orphagen Pharmaceuticals; Rakuten Medical; Seagen; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); IO Biotech (Inst); Merck; Merck (Inst)
Expert Testimony - Cel-Sci Corporation
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Sanofi (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron; Sanofi
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Jean-Pascal Machiels
Consulting or Advisory Role - ALX Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cue Biopharma; CureVac; Etherna; F-Star; Genmab; GlaxoSmithKline; Incyte; Innate Pharma; iTEOS Therapeutics; Janssen; Merck Senero; Merus; MSD Oncology; Nektar; Novartis; Pfizer; Roche; Seagan
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; Merck Serono; MSD; Pfizer
Other Relationship - PsiOxus Therapeutics